Camazol 5mg Dosage Information
Critical Clarification Required
There is no medication called "Camazol 5mg" in standard medical literature, and the expanded question incorrectly equates it with Bicalutamide, which is an entirely different drug class and indication.
The term "Camazol" does not appear in any of the provided evidence, FDA databases, or standard pharmaceutical references. However, if you are referring to Carbimazole (an antithyroid medication sometimes abbreviated colloquially), the typical dosing differs significantly from what is described. If you meant Bicalutamide (as suggested in the expanded question), this is a nonsteroidal antiandrogen used for prostate cancer.
If Referring to Bicalutamide (Casodex)
The standard dosage of bicalutamide is 50 mg once daily when used in combination therapy with an LHRH agonist for advanced prostate cancer, NOT 5 mg. 1, 2, 3
Approved Dosing Regimens
For Advanced Prostate Cancer (Combination Therapy):
- 50 mg orally once daily in combination with a luteinizing hormone-releasing hormone (LHRH) agonist or surgical castration 2, 3, 4
- This represents the standard FDA-approved dose for metastatic disease 1
For Early Non-Metastatic Prostate Cancer (Monotherapy):
- 150 mg orally once daily as monotherapy for locally advanced or early-stage disease 2, 5, 4
- The 150 mg dose provides equivalent survival outcomes compared with castration in patients with locally advanced prostate cancer 4
Pharmacokinetic Considerations
- Bicalutamide exhibits nonlinear pharmacokinetics above 50 mg daily doses, with steady-state concentrations increasing disproportionately 2
- The (R)-enantiomer (active form) has a plasma elimination half-life of approximately 1 week, allowing once-daily dosing 2
- Steady-state concentrations are reached after approximately 4-12 weeks of daily administration due to the long half-life 2
- Doses above 200-300 mg daily show plateau effects with no additional clinical benefit due to saturable absorption 5
Dose Modifications
Hepatic Impairment:
- Mild-to-moderate hepatic impairment does not require dose adjustment 2
- Severe hepatic impairment may result in slower elimination and requires caution 2
Renal Impairment:
- No dose adjustment needed regardless of degree of renal impairment 2
Common Pitfall
A 5 mg dose of bicalutamide has never been studied or approved and would be subtherapeutic. The minimum effective dose studied is 10 mg daily, with standard clinical doses being 50 mg or 150 mg depending on indication 5, 4. If you have a 5 mg tablet, this is likely a different medication entirely, and clarification of the actual drug name is essential before administration.